CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
OPERATING ACTIVITIES:
Net income (loss)	$ 43,229	$ 45,394	$ 32,337	$ 9,180	$ 123,691	$ 41,148
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					89,090	89,853
Non-cash impairment charges					2,754	0
Deferred income tax (benefit) provision					(13,498)	4,784
Share-based compensation					29,778	14,333
Amortization of debt issuance costs and expenses associated with debt refinancing					5,308	10,499
Non-cash lease expense					3,099	2,172
Accretion of bond issuance discount					0	11,075
Loss on disposal of property and equipment					2,029	559
Gain from the sale of business	230		0		(41,967)	0
Change in fair value of contingent consideration and others					(544)	(45)
Changes in assets and liabilities:
Accounts receivable					17,437	57,863
Inventories					(3,598)	(45,531)
Prepaid expenses and other current assets					(11,696)	(865)
Other non-current assets					5,900	10,868
Accounts payable, accrued expenses and other current liabilities					33,858	(67,178)
Contract liabilities					0	(548)
Other non-current liabilities					1,509	(5,417)
Net cash provided by operating activities					243,150	123,570
INVESTING ACTIVITIES:
Purchases of property and equipment					(20,595)	(30,463)
Proceeds from sale of Extremity Orthopedics business					190,468	0
Proceeds from sale of property and equipment					3	3,311
Cash paid for business acquisitions, net of cash acquired					(303,910)	0
Acquired in-process research and development					0	(5,000)
Net proceeds on swaps designated as net investment hedges					76	0
Net cash used in investing activities					(133,958)	(32,152)
FINANCING ACTIVITIES:
Proceeds from borrowings of long-term indebtedness					13,450	151,300
Payments on debt					(114,250)	(441,000)
Purchase of option hedge on convertible notes					0	(104,248)
Proceeds from convertible notes issuance					0	575,000
Proceeds from sale of stock purchase warrants					0	44,563
Payment of debt issuance costs					(249)	(24,347)
Purchases of treasury stock					0	(100,000)
Proceeds from exercised stock options					6,588	3,821
Cash taxes paid in net equity settlement					(4,286)	(4,686)
Net cash (used) provided by financing activities					(98,747)	100,403
Effect of exchange rate changes on cash and cash equivalents					(10,380)	5,547
Net increase in cash and cash equivalents					65	197,368
Cash and cash equivalents at beginning of period		$ 470,166		$ 198,911	470,166	198,911	$ 198,911
Cash and cash equivalents at end of period	$ 470,231		$ 396,279		$ 470,231	$ 396,279	$ 470,166